샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758154

세계의 섬망 시장

Delirium
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 281 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 섬망 시장은 2030년까지 4,150만 달러에 달할 전망

2024년에 3,270만 달러로 추정되는 세계의 섬망 시장은 2024-2030년에 CAGR 4.0%로 성장하며, 2030년에는 4,150만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 과활동형은 CAGR 5.0%를 기록하며, 분석 기간 종료시에는 2,460만 달러에 달할 것으로 예측됩니다. 저활동형 부문의 성장률은 분석 기간 중 CAGR 2.6%로 추정됩니다.

미국 시장은 890만 달러로 추정, 중국은 CAGR 7.6%로 성장 예측

미국의 섬망 시장은 2024년에 890만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 850만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 7.6%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.6%와 3.2%로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 것으로 예측됩니다.

세계의 섬망 치료 시장 - 주요 동향과 촉진요인 정리

섬망이 급성기 의료와 노인 의료에서 우선순위로 떠오르는 이유는 무엇인가?

섬망은 갑작스러운 착란, 방향 감각 상실, 의식 수준의 변동을 특징으로 하며, 입원 환자, 특히 노인, 중환자실 환자, 수술 후 환자에서 심각한 합병증으로 인식되고 있습니다. 그 영향은 과소평가되는 경향이 있지만, 섬망은 이환율 증가, 입원 기간 연장, 의료비 증가, 장기적인 인지 기능 저하 위험 증가와 관련이 있습니다. 전 세계 인구가 고령화되고 입원을 필요로 하는 만성질환의 부담이 증가함에 따라 의료 시스템 전반에 걸쳐 섬망 발생률이 급증하고 있습니다.

의료 서비스 프로바이더들은 특히 노인 병동, 수술 회복실, 중환자실 등에서 섬망의 조기 발견과 예방에 중점을 두고 있습니다. 이 병태는 일반적으로 감염, 다약제 병용, 대사 불균형, 취약한 환자의 급격한 환경 변화 등 여러 가지 위험 요인에 의해 발생합니다. 섬망은 더 이상 입원의 불가피한 부분이 아니라 예방 및 치료 가능한 증후군으로 인식되고 있으며, 효과적인 관리를 위해 약리학적, 비약리학적, 환경적 전략을 결합한 다학제적 프로토콜의 개발이 요구되고 있습니다.

섬망을 보다 효과적으로 감지하기 위해 진단 및 모니터링 툴은 어떻게 진화하고 있는가?

섬망의 조기 및 정확한 발견은 그 가변적인 특성과 치매 및 우울증과의 증상 중복으로 인해 여전히 중요한 과제입니다. 이에 Confusion Assessment Method(CAM), Intensive Care delirium Screening Checklist(ICDSC), 4AT 스크리닝 툴 등 표준화된 스크리닝 툴이 개발되어 널리 채택되고 있습니다. 널리 채택되고 있습니다. 이러한 장비는 현재 특히 응급실, 수술 회복실, 노인 병동 등의 임상 프로토콜에 필수적인 요소가 되고 있습니다. 지속적인 환자 모니터링 기술도 ICU에 통합되어 섬망의 발병을 알리는 인지 기능의 변화와 생리적 스트레스 지표를 추적할 수 있게 되었습니다.

디지털 헬스 혁신은 진단 분야에도 진출하고 있는데, AI를 활용한 임상 판단 지원 시스템이나 전자건강기록(EHR)과 연동된 경고 시스템은 실시간 임상 데이터를 기반으로 고위험군 환자를 식별하기 위해 도입되고 있습니다. 이러한 플랫폼은 투약 검토, 환경 개선, 수분 보충 지원, 감각 방향 전환 등 적시에 개입할 수 있도록 돕습니다. 비전문가 간병인을 위해 설계된 모바일 앱과 침대 옆 평가 툴도 주목받고 있으며, 재택 및 장기요양시설에서 발견율을 높이는 데 도움이 되고 있습니다.

섬망 관리에서 어떤 치료 전략이 효과적일까요?

섬망의 관리는 예방, 조기 개입, 근본적인 유발 요인을 최소화하는 데 중점을 둡니다. 비약리학적 중재는 특히 노인이나 수술 후 환자에서 예방과 치료 모두에서 가장 중요한 역할을 합니다. 여기에는 오리엔테이션 전략, 수면 위생 프로토콜, 소음 감소, 통증 관리, 감각 차단을 줄이기 위한 시각 및 청각 보조 장비 등이 포함됩니다. 병원 노인 생활 프로그램(HELP)과 같은 복합적 케어 모델은 섬망의 위험 요인을 체계적으로 다루고 환자의 예후를 개선하기 위해 병원에서 채택되고 있습니다.

약리학적 치료는 일반적으로 심한 흥분이나 타인에 대한 위험성이 있는 경우에만 시행됩니다. 할로페리돌과 같은 항정신병제물이나 퀘티아핀이나 올란자핀과 같은 비정형 약물이 사용되기도 하지만, 일상적인 사용을 지지하는 증거는 아직 다양합니다. 수면-각성 주기를 안정화시키는 멜라토닌이나 덱스메데토미딘, 인지 손상을 최소화하는 신경보호제 등 대체 약물요법에 대한 연구도 진행 중입니다. 기본적인 인지 상태, 동반 질환, 약물 민감도를 고려한 개별화된 의료 접근은 섬망 치료 경로에서 점점 더 중요해지고 있습니다.

섬망 관리 시장 확대를 촉진하는 주요 요인은?

섬망 관리 시장의 성장은 전 세계 노인 인구 증가, 만성질환 환자의 입원율 증가, 섬망의 위험과 결과에 대한 의료 전문가들의 인식 증가 등 여러 요인에 기인합니다. 병원이 재입원율, 중환자실 합병증, 장기적인 인지 기능 장애를 줄이기 위해 노력하는 가운데, 섬망 예방 프로토콜은 전반적인 의료 질 관리 구상의 일환으로 우선순위를 두고 있습니다. 국가 의료기관 및 인증 기관은 안전 기준 및 성과 기준의 일부로 섬망 평가를 의무화하고 있습니다.

EHR 기반 스크리닝 툴, AI를 활용한 임상적 판단 지원, 웨어러블 인지기능 모니터링 기기는 발견 및 관리 프로세스를 효율화합니다. 이와 함께 노인병 전문의, 신경과 전문의, 간호사, 약사 등 다학제 진료팀의 확대로 치료 접근법의 표준화가 강화되고 있습니다. 재택 치료의 활성화와 수술 후 또는 중환자실 입원 후 원격 모니터링도 지역 단위의 케어 솔루션과의 연관성을 높이고 있습니다. 의료 시스템이 신경인지 합병증에 보다 적극적으로 대처함에 따라 섬망 치료 및 모니터링 영역은 임상적으로나 상업적으로나 크게 확대될 것입니다.

부문

유형(과활동형, 저활동형, 혼합형); 최종 사용(병원 최종 사용, 전문의료 최종 사용, 연구 센터 최종 사용)

조사 대상 기업의 예

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Akorn Incorporated
  • Alkermes plc
  • Apotex Inc.
  • BioXcel Therapeutics, Inc.
  • Ceribell, Inc.
  • Delix Therapeutics
  • Eleusis Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mind Medicine(MindMed) Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.15

Global Delirium Market to Reach US$41.5 Million by 2030

The global market for Delirium estimated at US$32.7 Million in the year 2024, is expected to reach US$41.5 Million by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Hyperactive Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$24.6 Million by the end of the analysis period. Growth in the Hypoactive Type segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.9 Million While China is Forecast to Grow at 7.6% CAGR

The Delirium market in the U.S. is estimated at US$8.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Delirium Treatment Market - Key Trends & Drivers Summarized

Why Is Delirium Emerging as a Priority Concern in Acute and Elderly Care?

Delirium, characterized by a sudden onset of confusion, disorientation, and fluctuating levels of consciousness, is increasingly recognized as a serious complication in hospitalized patients-especially among the elderly, ICU patients, and post-operative individuals. Its impact is often underestimated, yet delirium is associated with increased morbidity, prolonged hospital stays, higher healthcare costs, and a greater risk of long-term cognitive decline. As global populations age and the burden of chronic illnesses requiring hospitalization rises, the incidence of delirium is surging across healthcare systems.

Healthcare providers are placing growing emphasis on early identification and prevention of delirium, especially in geriatric wards, surgical recovery units, and intensive care settings. The condition is commonly triggered by multiple risk factors such as infections, polypharmacy, metabolic imbalances, and sudden environmental changes in vulnerable patients. Delirium is no longer viewed as an inevitable part of hospitalization but as a preventable and treatable syndrome, prompting the development of multidisciplinary protocols that combine pharmacological, non-pharmacological, and environmental strategies to manage it effectively.

How Are Diagnostic and Monitoring Tools Evolving to Detect Delirium More Effectively?

Early and accurate detection of delirium remains a critical challenge due to its fluctuating nature and symptom overlap with dementia and depression. This has led to the development and widespread adoption of standardized screening tools such as the Confusion Assessment Method (CAM), the Intensive Care Delirium Screening Checklist (ICDSC), and the 4AT screening tool. These instruments are now integral to clinical protocols, especially in emergency departments, surgical recovery, and geriatric care units. Continuous patient monitoring technologies are also being integrated into ICU settings to track cognitive fluctuations and physiological stress indicators that may signal the onset of delirium.

Digital health innovations are also entering the diagnostic space. AI-powered clinical decision support systems and electronic health record (EHR)-linked alert systems are being deployed to identify high-risk patients based on real-time clinical data. These platforms enable timely interventions such as medication review, environmental modification, hydration support, and sensory reorientation. Mobile apps and bedside assessment tools designed for non-specialist caregivers are also gaining attention, helping improve detection rates in home care and long-term care facilities.

What Therapeutic Strategies Are Gaining Ground in the Management of Delirium?

Management of delirium emphasizes prevention, early intervention, and minimizing underlying triggers. Non-pharmacological interventions remain the gold standard for both prevention and treatment, especially in elderly and post-operative patients. These include orientation strategies, sleep hygiene protocols, noise reduction, pain management, and vision/hearing aids to reduce sensory deprivation. Multicomponent care models such as the Hospital Elder Life Program (HELP) are being adopted by hospitals to systematically address delirium risk factors and improve patient outcomes.

Pharmacological treatments are typically reserved for cases of severe agitation or risk to self and others. Antipsychotics such as haloperidol and atypical agents like quetiapine and olanzapine are sometimes used, although evidence supporting their routine use remains mixed. Research into alternative pharmacotherapies is ongoing, including melatonin and dexmedetomidine for sleep-wake cycle stabilization and neuroprotective agents to minimize cognitive injury. Personalized medicine approaches that account for underlying cognitive status, co-morbidities, and drug sensitivity are becoming increasingly important in delirium care pathways.

What Are the Main Forces Driving the Expansion of the Delirium Management Market?

The growth in the delirium management market is driven by several factors, including the rising global geriatric population, increased hospitalization rates among patients with chronic conditions, and growing awareness among healthcare professionals about the risks and consequences of delirium. As hospitals seek to reduce readmission rates, ICU complications, and long-term cognitive impairment, delirium prevention protocols are being prioritized as part of overall quality care initiatives. National health agencies and accreditation bodies are mandating delirium assessment as part of safety and performance standards.

Technological integration is another growth catalyst, with EHR-based screening tools, AI-enabled clinical decision support, and wearable cognitive monitoring devices streamlining the detection and management process. In parallel, the expansion of multidisciplinary care teams involving geriatricians, neurologists, nurses, and pharmacists is enhancing the standardization of treatment approaches. The push for home-based recovery and remote monitoring post-surgery or ICU stay is also increasing the relevance of community-level delirium care solutions. As healthcare systems become more proactive in addressing neurocognitive complications, the delirium treatment and monitoring landscape is set for significant clinical and commercial expansion

SCOPE OF STUDY:

The report analyzes the Delirium market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hyperactive Type, Hypoactive Type, Mixed Type); End-Use (Hospitals End-Use, Specialty Care End-Use, Research Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Akorn Incorporated
  • Alkermes plc
  • Apotex Inc.
  • BioXcel Therapeutics, Inc.
  • Ceribell, Inc.
  • Delix Therapeutics
  • Eleusis Ltd.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mind Medicine (MindMed) Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Delirium - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Hospitalization of Elderly Patients Propels Incidence and Diagnosis of Delirium
    • Increased Awareness Among Healthcare Providers Strengthens Early Detection and Clinical Management
    • Expansion of Geriatric Healthcare Infrastructure Throws the Spotlight on Acute Cognitive Impairments
    • Adoption of Screening Tools and Assessment Protocols Enhances Diagnostic Accuracy in ICU Settings
    • Growth in Post-Surgical and Trauma-Related Hospital Admissions Fuels Acute Delirium Cases
    • Use of Benzodiazepines and Polypharmacy in Elderly Populations Drives Risk of Delirium Onset
    • Rising Demand for Non-Pharmacological Interventions Promotes Multidisciplinary Care Programs
    • Regulatory Emphasis on Patient Safety and Cognitive Monitoring Supports ICU Delirium Protocols
    • Integration With Hospital EMR and Alert Systems Enhances Monitoring of High-Risk Patients
    • Increased Research on Delirium-Associated Mortality Promotes Investment in Preventive Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Delirium Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Delirium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Delirium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hyperactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hyperactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hyperactive Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hypoactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hypoactive Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hypoactive Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mixed Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mixed Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Mixed Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Care End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Care End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Care End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Research Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Delirium by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Delirium by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Delirium by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Delirium by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Delirium by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Delirium by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Delirium by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Delirium by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Delirium by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Delirium Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Delirium by Type - Hyperactive Type, Hypoactive Type and Mixed Type Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Delirium by Type - Percentage Breakdown of Value Sales for Hyperactive Type, Hypoactive Type and Mixed Type for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Delirium by End-Use - Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Delirium by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Care End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제